These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38945955)

  • 1. PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways.
    Lim SH; Lee H; Lee HJ; Kim K; Choi J; Han JM; Min DS
    Exp Mol Med; 2024 Jul; 56(7):1479-1487. PubMed ID: 38945955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
    Kang DW; Lee BH; Suh YA; Choi YS; Jang SJ; Kim YM; Choi KY; Min DS
    Clin Cancer Res; 2017 Dec; 23(23):7340-7350. PubMed ID: 28939743
    [No Abstract]   [Full Text] [Related]  

  • 4. Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
    He F; Chen H; Yang P; Wu Q; Zhang T; Wang C; Wei J; Chen Z; Hu H; Li W; Cao J
    Oncotarget; 2016 Dec; 7(49):81156-81171. PubMed ID: 27835604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
    Prossomariti A; Piazzi G; Alquati C; Ricciardiello L
    Cell Mol Gastroenterol Hepatol; 2020; 10(3):491-506. PubMed ID: 32334125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway.
    Liu X; Su K; Sun X; Jiang Y; Wang L; Hu C; Zhang C; Lu M; Du X; Xing B
    J Exp Clin Cancer Res; 2021 Apr; 40(1):132. PubMed ID: 33858476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
    He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A
    Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
    Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
    J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-30-5p suppresses cell chemoresistance and stemness in colorectal cancer through USP22/Wnt/β-catenin signaling axis.
    Jiang S; Miao D; Wang M; Lv J; Wang Y; Tong J
    J Cell Mol Med; 2019 Jan; 23(1):630-640. PubMed ID: 30338942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
    Tomar VS; Patil V; Somasundaram K
    Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells.
    Kang DW; Min do S
    PLoS One; 2010 Aug; 5(8):e12109. PubMed ID: 20711340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between PI3K/Akt and Wnt/β-catenin pathways promote colorectal cancer progression regardless of mutational status.
    Fleming-de-Moraes CD; Rocha MR; Tessmann JW; de Araujo WM; Morgado-Diaz JA
    Cancer Biol Ther; 2022 Dec; 23(1):1-13. PubMed ID: 35944058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
    Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
    J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitin-Specific Peptidase 22 Contributes to Colorectal Cancer Stemness and Chemoresistance via Wnt/β-Catenin Pathway.
    Jiang S; Song C; Gu X; Wang M; Miao D; Lv J; Liu Y
    Cell Physiol Biochem; 2018; 46(4):1412-1422. PubMed ID: 29689565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.
    Belur Nagaraj A; Knarr M; Sekhar S; Connor RS; Joseph P; Kovalenko O; Fleming A; Surti A; Nurmemmedov E; Beltrame L; Marchini S; Kahn M; DiFeo A
    Cancer Res; 2021 Apr; 81(8):2044-2055. PubMed ID: 33574092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.
    Barzegar Behrooz A; Talaie Z; Jusheghani F; Łos MJ; Klonisch T; Ghavami S
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospholipase D meets Wnt signaling: a new target for cancer therapy.
    Kang DW; Choi KY; Min do S
    Cancer Res; 2011 Jan; 71(2):293-7. PubMed ID: 21224347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Wnt/β-catenin signaling pathway in cancer.
    Zhang Y; Wang X
    J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
    Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
    Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.